- Moderna plans to raise $2 billion through notes exchangeable for shares and use the proceeds for its cancer vaccine business and debt repayment.
- The convertible notes are due in 2032, and Moderna has an option to sell an additional $300 million.
Quotes
“Moderna Inc. plans to raise $2 billion from selling notes that can be exchanged for shares, which it will use to invest in its cancer vaccine business and repay debt.”
“The Cambridge, Massachusetts-based biotechnology company will sell $2 billion worth of convertible senior notes due 2032, with an option to sell a further $300 million”